The Medicines Company

  • A Sensible Acquisition by This Healthcare Company

    By usman iftikhar - August 15, 2013 | Tickers: ENDP, PFE, MDCO

    As competition gets stronger, companies attempt to consolidate operations. Although this consolidation is an expensive way to penetrate the market, in the pharmaceutical industry, this method brings safer growth. The smaller players especially are aiming to integrate with those who have their products in the second or third phases of clinical trials.

    That same strategy has been used by The Medicines Company (NASDAQ: MDCO). After passing the last stage of more »

  • A Small-Cap Pharmaceutical Company With 2014 in Its Sights

    By Ashley Sales - July 5, 2013 | Tickers: AZN, BMY, MDCO

    A few months back, Barron's featured an intriguing pharmaceutical company that goes by the name The Medicines Company (NASDAQ: MDCO). This stock is said to have strong catalysts that could lift the share price over the years. The company was at $20.40/share in November 2012 and is now trading at $31.60. The company has reported a 52-week high of $37.40.

    The biggest catalyst for a more »

  • Pipeline Probe: Alnylam

    By Brandy Betz - June 20, 2013 | Tickers: ALNY, SNY, MDCO

    Shares of biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) have soared over 160% in the past year. The company's a leader in developing drugs and delivery systems centered on RNA interference, or RNAi, It's an emerging area that could see major gains in the future for the companies at the forefront. And Alnylam's at the forefront. 

    The past year has ushered in new drug alliances with The Medicines Company more »

  • Is There a Future for Small Pharma?

    By Chris Hodge - May 23, 2013 | Tickers: CBST, MDCO, UTHR

    Small pharma is fighting an uphill battle. Fortunately, this is precisely what inspires a lot of companies to reach for the heavens. Unfortunately, the huge costs associated with taking a medicine from being a great idea to a great product on store shelves is one that can easily leave a smaller company broken and derelict. Let's see how some of the smallest drug makers in the world are likely more »

  • This Small Cap Pharmaceutical Stock Looks Interesting

    By Anh HOANG - April 17, 2013 | Tickers: AZN, BMY, MDCO

    Recently, Barron’s featured one pharmaceutical firm having potential catalysts that could drive its share price higher. That pharmaceutical firm is The Medicines (NASDAQ: MDCO). Since the middle of November 2012, The Medicines has advanced significantly, from around $20.40 per share to around $33 per share.

    The Medicines has four drugs, which might have FDA approval next year. Receiving FDA approval has always been a significant positive catalyst for more »

  • This Smallcap Pharmaceutical Stock is Opportunistic

    By Anh HOANG - April 14, 2013 | Tickers: AZN, BMY, MDCO

    Recently, Barron’s featured one pharmaceutical firm that could have potential catalyst to drive its share price higher. That pharmaceutical firm is The Medicines Co (NASDAQ: MDCO). Since the middle of November 2012, The Medicines has advanced significantly, from around $20.40 per share to around $33 per share. The Medicines have four drugs, which might have FDA approval next year. Receiving FDA approval has always been a significant positive more »

  • 3 Earning Results that Could Lead to a Long-Term Trend Higher

    By Brian Nichols - February 20, 2013 | Tickers: HLF, HD, LL, MDCO

    Earnings and earning-related news is the number one catalyst for stock movement. A strong quarter can dictate the direction of a stock for the following three months as can a bad quarter; in the past I have written in detail about such subjects, a domino effect following a strong or bad quarter. In this piece I am looking at three stocks that might see a long-term trend as a result more »

  • The Good, The Bad, and The Ugly with The Medicines Company

    By Josef Ray Dagatan - January 17, 2013 | Tickers: CELG, PPHM, MDCO

    After the extravagant flair of celebrating Thanksgiving, Christmas, and New Year wears off, it’s common for a lot of people to pay more keen attention to their health. After all, when the guests have left and the parties are over, you tend to notice that you gained more than just a few unwanted pounds; you also increased your chances of getting sick and acquiring illnesses. In my opinion, being more »

  • Is Celgene All Good as a Long-Term Investment?

    By Rhodora Dagatan - January 15, 2013 | Tickers: ACHC, CELG, MDCO

    Celgene Corporation (NASDAQ: CELG), a multinational biopharmaceutical company based in Summit, New Jersey, primarily produces drug treatments for cancer and inflammatory diseases, and takes part in the detection, advancement, and commercialization of therapies intended to provide a breakthrough in the field of medicine.  Since its establishment in 1986, the company has been investing in research and progress, as well as providing products such as Thalomid (thalidomide), Revlimid (lenalidomide), Vidaza (azacitidine more »

  • Biotech Gets a Boost on Tuesday, but Will it Continue

    By Brian Nichols - January 10, 2013 | Tickers: ARNA, CTIC, STSI, MDCO

    It doesn’t matter if the market trades higher or lower by 2%, the biotechnology industry and its components march to the beat of their own drum. Every year biotech stocks lead the market in being the best performers, and it’s almost always a small or midcap stock that rallies to post large gains. Therefore, in this article I am looking at four stocks that rallied higher on Tuesday more »

  • Billionaire Steve Cohen Bought This Drug Manufacturer

    By Meena Krishnamsetty - November 21, 2012 | Tickers: CBST, PCYC, MDCO, UTHR, WCRX

    According to a filing with the SEC, Steve Cohen’s SAC Capital Advisors had acquired a total of 2.7 million shares of The Medicines Company (NASDAQ: MDCO) giving it 5.0% of the shares outstanding (and thus triggering the filing of the 13G). SAC’s 13F filing for the third quarter of the year shows that it owned 1.6 million shares at the end of September, which had more »

  • J.P. Morgan Healthcare Conference Schedule: Day One

    By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

    The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

    I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUSmore »)